Welcome to our dedicated page for 4D Molecular Therapeutics news (Ticker: FDMT), a resource for investors and traders seeking the latest updates and insights on 4D Molecular Therapeutics stock.
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) is a late-stage biotechnology company developing durable, disease-targeted genetic medicines. News about 4D Molecular Therapeutics often focuses on progress in its lead programs, 4D-150 for retinal vascular diseases and 4D-710 for cystic fibrosis lung disease, as well as corporate, financial and partnership developments.
For ophthalmology, company updates highlight clinical data and milestones for 4D-150 in wet age-related macular degeneration and diabetic macular edema. These include interim results from the PRISM Phase 1/2 trial, enrollment and design details for the 4FRONT Phase 3 program, and plans for global Phase 3 trials in DME. News items also cover collaborations, such as the license and development agreement with Otsuka Pharmaceutical for 4D-150 in Asia-Pacific markets.
In pulmonology, 4DMT news includes interim clinical data from the AEROW Phase 1/2 trial of 4D-710 in cystic fibrosis lung disease, describing CFTR transgene expression, lung function measures and dose selection for Phase 2. Additional coverage addresses external support, including an equity investment from the Cystic Fibrosis Foundation to help advance 4D-710.
Investors can also find announcements on equity offerings, cash runway guidance, leadership changes, board appointments, employment inducement grants and participation in healthcare and investor conferences. This news page aggregates these updates so readers can follow clinical progress, strategic partnerships, capital markets activity and governance developments related to FDMT over time.
4D Molecular Therapeutics (Nasdaq: FDMT) announced on January 17, 2026 that its compensation committee granted 23,600 Restricted Stock Units (RSUs) on January 13, 2026 to four new non-executive employees.
The RSUs were issued under the company’s 2025 Employment Inducement Award Plan, which the board approved in February 2025 under Nasdaq Rule 5635(c)(4) to permit equity grants that induce new hires to join the company.
4D Molecular Therapeutics (Nasdaq: FDMT) provided a 2026 corporate update highlighting accelerated late-stage retinal programs, leadership changes and financial runway. Key clinical milestones include an increased 4FRONT Phase 3 target enrollment to 480 patients per trial (≈90% power), 381 patients randomized or approved to randomize in 4FRONT-1 as of Jan 6, 2026, with North America enrollment on track to complete in Q1 2026 and topline data expected in H1 2027. Ex-U.S. enrollment for 4FRONT-2 aims to finish in H2 2026 with topline in H2 2027. PRISM 2-year Phase 2b data expected mid-2026; SPECTRA 2-year data and DME Phase 3 plans expected in H2 2026. Leadership updates include board addition Glenn Sblendorio and executive promotions, and cash of $514 million is expected to fund operations into H2 2028.
4D Molecular Therapeutics (Nasdaq: FDMT) announced positive interim Phase 1 AEROW data for 4D-710 in cystic fibrosis lung disease (data cutoff Dec 1, 2025).
Key points: 16 participants enrolled across four dose cohorts (2E15, 1E15, 5E14, 2.5E14 vg) with follow-up from 4 months to 3.5 years. The company selected 2.5E14 vg as the Phase 2 dose after dose-dependent, durable CFTR transgene expression at or above physiologically relevant levels and clinically meaningful improvements in ppFEV1, LCI2.5 and CFQ-R through 1 year. Safety: no new pulmonary or other safety events in higher-dose cohorts; lower-dose AEs were generally mild and transient. Next milestones: complete Phase 2 dose-expansion (target n=6) in H1 2026; program update in H2 2026.
4D Molecular Therapeutics (Nasdaq: FDMT) announced that on December 9, 2025 its compensation committee granted 13,800 Restricted Stock Units (RSUs) to three new non-executive employees under the company’s 2025 Employment Inducement Award Plan.
The inducement plan was approved by the board in February 2025 and is being used pursuant to Rule 5635(c)(4) of The Nasdaq Global Market to attract new hires.
4D Molecular Therapeutics (NASDAQ: FDMT) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan 14, 2026. The presentation is scheduled for 7:30 a.m. PT and will be available via webcast.
Members of 4DMT management will be available for one-on-one meetings. An archived copy of the webcast will be available for up to one year in the company’s Investors events section at the investor website.
4D Molecular Therapeutics (Nasdaq: FDMT) announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference and will be available for one-on-one meetings.
The presentation is scheduled for Wednesday, Dec 3, 2025 at 2:35 p.m. ET. A live webcast will be available and archived copies will remain on the company's Investors website for up to one year.
4D Molecular Therapeutics (Nasdaq: FDMT) appointed Kristian Humer as Chief Financial Officer effective Nov 17, 2025. He will lead financial planning, capital allocation, corporate development and strategic initiatives as the company advances multiple Phase 3 programs and prepares for commercial readiness.
Humer brings more than 20 years of finance experience, including senior roles at Citi healthcare investment banking (2010–2021) and prior CFO positions at Foghorn Therapeutics and Viridian Therapeutics. He holds an MBA from Duke Fuqua and a BA (Hons) in accounting and economics from the University of Reading.
4D Molecular Therapeutics (Nasdaq: FDMT) announced on November 14, 2025 that its compensation committee granted 45,400 restricted stock units (RSUs) on November 11, 2025 to four new non-executive employees.
The awards were made under the company’s 2025 Employment Inducement Award Plan, which the board approved in February 2025 pursuant to Nasdaq Rule 5635(c)(4) to induce new hires to join the company.
4D Molecular Therapeutics (NASDAQ: FDMT) reported Q3 2025 results and operational highlights on Nov 10, 2025.
Key items: an $85 million upfront APAC license payment from Otsuka plus an expected ≥$50 million in cost sharing; eligibility for up to $336 million in milestones and tiered double-digit royalties; $372 million cash as of Sep 30, 2025; ~$93 million net proceeds from an equity offering; up to $11 million CF Foundation investment (first tranche $7.5M received).
Clinical: positive long-term PRISM Phase 1/2 wet AMD data (1.5–2 years), 4FRONT-1 >200 randomized and on track for Q1 2026 enrollment completion.
4D Molecular Therapeutics (Nasdaq: FDMT) said its management team will participate in a fireside chat and be available for one-on-one meetings at the Jefferies 2025 London Healthcare Conference.
The presentation is scheduled for Tuesday, Nov 18, 2025 at 9:00 a.m. GMT. A live webcast will be available, and archived copies will be posted for up to one year in the Investors section of the company's website.
FAQ
What is the current stock price of 4D Molecular Therapeutics (FDMT)?
What is the market cap of 4D Molecular Therapeutics (FDMT)?
